Skip to main content
SpringerLink
Log in

FDA updates labelling for dronedarone with CV, death risk

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. FDA.FDA Drug Safety Communication: Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. Internet Document: 19 Dec 2011. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

FDA updates labelling for dronedarone with CV, death risk. React. Wkly. 1383, 1 (2012). https://doi.org/10.2165/00128415-201213830-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213830-00001

Keywords

Search

Navigation